Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atrium Therapeutics, Inc.RNA · Entity 6185 | Director | September 18, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atrium Therapeutics, Inc.
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,974 |
Reported balance
After 2026-09-18 transaction · row 1
1 source rowRow 1 · 2026-09-18 · Tax withholding · Disposed 22,812 · Balance 31,974 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 150,365 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.75 · Expires 2031-01-20 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.22 · Expires 2032-01-20 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 66,500 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.47 · Expires 2033-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 96,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.57 · Expires 2033-09-10 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 72,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.16 · Expires 2034-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-27 · Disposition to issuer · Disposed 88,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.42 · Expires 2035-01-05 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-27 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 22, 2026 20:20 UTC | Atrium Therapeutics, Inc. RNA · Entity 6185 | Tax withholdingCommon Stock | 22,812 | $8.95 | $204,167.40 |
DisclosureSEC source: 0001193125-26-397955 · ownership.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,974 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:16 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $31.42 | Not disclosed |
DisclosureSEC source: 0001193125-26-082261 · ownership.xml · derivative · entry 7 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2035-01-05 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:16 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 88,000 | Not disclosed Strike: $10.16 | Not disclosed |
DisclosureSEC source: 0001193125-26-082261 · ownership.xml · derivative · entry 6 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,000 shares Expires 2034-01-19 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:16 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 72,000 | Not disclosed Strike: $6.57 | Not disclosed |
DisclosureSEC source: 0001193125-26-082261 · ownership.xml · derivative · entry 5 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,000 shares Expires 2033-09-10 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:16 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 96,000 | Not disclosed Strike: $22.47 | Not disclosed |
DisclosureSEC source: 0001193125-26-082261 · ownership.xml · derivative · entry 4 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,000 shares Expires 2033-01-19 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:16 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 66,500 | Not disclosed Strike: $14.22 | Not disclosed |
DisclosureSEC source: 0001193125-26-082261 · ownership.xml · derivative · entry 3 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,500 shares Expires 2032-01-20 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:16 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $26.75 | Not disclosed |
DisclosureSEC source: 0001193125-26-082261 · ownership.xml · derivative · entry 2 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2031-01-20 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:16 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerCommon Stock | 150,365 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-082261 · ownership.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. F1 · price: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 18:00 UTC | Atrium Therapeutics, Inc. RNA · Entity 6185 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.75 | $0.00 |
DisclosureSEC source: 0001193125-26-085919 · ownership.xml · derivative · entry 1 Flanagan W. Michael · CIK 0001841990 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:33 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 2,558 | $72.45 | $185,327.10 |
DisclosureSEC source: 0001599901-26-000024 · wk-form4_1769207633.xml · nonDerivative · entry 2 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,093 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2026 and the sale of the resulting shares of common stock on January 21, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:33 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 3,976 | $72.45 | $288,061.20 |
DisclosureSEC source: 0001599901-26-000024 · wk-form4_1769207633.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,651 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2026 and the sale of the resulting shares of common stock on January 21, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:12 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 2,373 | $72.23 | $171,401.79 |
DisclosureSEC source: 0001599901-26-000008 · wk-form4_1767996754.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,627 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 6, 2026 and the sale of the resulting shares of common stock on January 7, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 13:30 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Tax withholdingCommon Stock | 13,695 | $71.87 | $984,259.65 |
DisclosureSEC source: 0001599901-25-000223 · wk-form4_1766151000.xml · nonDerivative · entry 2 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,000 F2 · balance_after: Represents the number of shares withheld by the Issuer to cover tax withholding in connection with the settlement of PSUs on December 17, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 13:30 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-25-000223 · wk-form4_1766151000.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,695 F1 · balance_after: Represents shares acquired upon the vesting of performance-based restricted stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on October 30, 2024. The PSUs were accelerated and settled on December 17, 2025 for tax planning purposes and such shares remain subject to recoupment by the Issuer if the Reporting Person's employment is terminated by the Issuer for cause or by the Reporting Person without good reason. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 20:07 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001599901-25-000184 · wk-form4_1757707665.xml · derivative · entry 3 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,500 Underlying: Common Stock · 20,000 shares Expires 2032-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported in this report were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F3 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 3, 2022 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 20:07 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 20,000 | $38.94 | $778,702.00 |
DisclosureSEC source: 0001599901-25-000184 · wk-form4_1757707665.xml · nonDerivative · entry 2 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,195 F1 · kind: The exercise and sales reported in this report were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.85 to $41.52. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 20:07 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 20,000 | $14.22 | $284,400.00 |
DisclosureSEC source: 0001599901-25-000184 · wk-form4_1757707665.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported in this report were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 22:18 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001599901-25-000113 · wk-form4_1749766731.xml · derivative · entry 3 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,500 Underlying: Common Stock · 20,000 shares Expires 2032-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported in this report were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F3 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 3, 2022 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 22:18 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 20,000 | $32.88 | $657,694.00 |
DisclosureSEC source: 0001599901-25-000113 · wk-form4_1749766731.xml · nonDerivative · entry 2 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,195 F1 · kind: The exercise and sales reported in this report were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.99 to $33.60. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 22:18 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 20,000 | $14.22 | $284,400.00 |
DisclosureSEC source: 0001599901-25-000113 · wk-form4_1749766731.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported in this report were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 22:40 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 11,780 | $31.06 | $365,867.95 |
DisclosureSEC source: 0001599901-25-000071 · wk-form4_1742596819.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,195 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of 25,000 time-based restricted stock units (RSUs) that vested on March 19, 2025. Those RSUs were initially granted as performance-based restricted stock units (PSUs), and converted to time-based RSUs as a result of a performance objective achieved by the Issuer on September 19, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.96 to $31.06. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 20:23 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001599901-25-000063 · wk-form4_1741811027.xml · derivative · entry 3 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,500 Underlying: Common Stock · 20,000 shares Expires 2032-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported in this report were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F3 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 3, 2022 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 20:23 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 20,000 | $30.13 | $602,614.00 |
DisclosureSEC source: 0001599901-25-000063 · wk-form4_1741811027.xml · nonDerivative · entry 2 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,975 F1 · kind: The exercise and sales reported in this report were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.56. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 20:23 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 20,000 | $14.22 | $284,400.00 |
DisclosureSEC source: 0001599901-25-000063 · wk-form4_1741811027.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported in this report were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 01:12 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 1,812 | $28.59 | $51,808.70 |
DisclosureSEC source: 0001599901-25-000037 · wk-form4_1737681121.xml · nonDerivative · entry 2 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,975 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2025 and the sale of the resulting shares of common stock on January 21, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $28.89. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 01:12 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 3,860 | $28.60 | $110,383.26 |
DisclosureSEC source: 0001599901-25-000037 · wk-form4_1737681121.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,787 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2025 and the sale of the resulting shares of common stock on January 21, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $29.63. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 01:35 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $31.42 | $0.00 |
DisclosureSEC source: 0001599901-25-000029 · wk-form4_1736386545.xml · derivative · entry 2 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-05 F2 · derivative.exercise_date: This option vests in 48 equal installments on each monthly anniversary of the grant date, until it is fully vested on January 6, 2029. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 01:35 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-25-000029 · wk-form4_1736386545.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,647 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 6, 2025, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 23:17 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 12,742 | $32.66 | $416,153.72 |
DisclosureSEC source: 0001599901-24-000207 · wk-form4_1734650256.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,647 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of 25,000 time-based restricted stock units (RSUs) that vested on December 17, 2024. Those RSUs were initially granted as performance-based restricted stock units (PSUs), and converted to time-based RSUs as a result of a performance objective achieved by the Issuer on June 17, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.66 to $32.66. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 23:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001599901-24-000197 · wk-form4_1734131313.xml · derivative · entry 3 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,000 Underlying: Common Stock · 24,000 shares Expires 2033-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F3 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 23:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 24,000 | $35.77 | $858,400.80 |
DisclosureSEC source: 0001599901-24-000197 · wk-form4_1734131313.xml · nonDerivative · entry 2 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,389 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.37 to $36.46. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 23:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 24,000 | $22.47 | $539,280.00 |
DisclosureSEC source: 0001599901-24-000197 · wk-form4_1734131313.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:09 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $26.75 | $0.00 |
DisclosureSEC source: 0001599901-24-000166 · wk-form4_1727986134.xml · derivative · entry 3 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 62,500 shares Expires 2031-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on January 21, 2022, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:09 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 62,500 | $47.62 | $2,976,112.50 |
DisclosureSEC source: 0001599901-24-000166 · wk-form4_1727986134.xml · nonDerivative · entry 2 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,389 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $48.20. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:09 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 62,500 | $26.75 | $1,671,875.00 |
DisclosureSEC source: 0001599901-24-000166 · wk-form4_1727986134.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 01:03 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 11,847 | $43.89 | $519,995.63 |
DisclosureSEC source: 0001599901-24-000160 · wk-form4_1727139809.xml · nonDerivative · entry 4 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,389 F5 · shares: The sales reported on this row were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F6 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $44.47. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 01:03 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 13,153 | $44.00 | $578,737.26 |
DisclosureSEC source: 0001599901-24-000160 · wk-form4_1727139809.xml · nonDerivative · entry 2 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,718 F2 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of those PSUs that vested on September 19, 2024 as a result of achievement of the Performance Condition. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.00 to $44.08. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 19, 2024 Filed Sep 24, 2024 01:03 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-24-000160 · wk-form4_1727139809.xml · nonDerivative · entry 3 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,718 F4 · shares: As a result of the achievement of the Performance Condition, on September 19, 2024, an additional 25,000 PSUs were earned by the Reporting Person. On such date, such PSUs converted to time-based restricted stock units that will vest in full on March 19, 2025, subject to the Reporting Person's continued employment or service through such date. Read SEC document |
| September 19, 2024 Filed Sep 24, 2024 01:03 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-24-000160 · wk-form4_1727139809.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,871 F1 · shares: Represents performance-based restricted stock units (PSUs). Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on September 11, 2023, and are eligible to vest upon the achievement of two company performance objectives. The PSUs reflected in this row represent the portion of the award that vested as a result of the achievement of the second performance objective (the Issuer's completion of a clinical event related to del-brax) (the Performance Condition). Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:25 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001599901-24-000152 · wk-form4_1726259097.xml · derivative · entry 7 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 34,000 shares Expires 2033-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F7 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:25 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $26.75 | $0.00 |
DisclosureSEC source: 0001599901-24-000152 · wk-form4_1726259097.xml · derivative · entry 6 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 62,500 shares Expires 2031-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on January 21, 2022, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:25 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 14,894 | $40.40 | $601,675.90 |
DisclosureSEC source: 0001599901-24-000152 · wk-form4_1726259097.xml · nonDerivative · entry 5 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,871 F4 · kind: The sales reported on this row were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F5 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.70 to $40.95. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:25 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 34,000 | $40.40 | $1,373,555.80 |
DisclosureSEC source: 0001599901-24-000152 · wk-form4_1726259097.xml · nonDerivative · entry 4 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,765 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.80 to $41.00. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:25 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 34,000 | $22.47 | $763,980.00 |
DisclosureSEC source: 0001599901-24-000152 · wk-form4_1726259097.xml · nonDerivative · entry 3 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:25 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 62,500 | $40.40 | $2,525,012.50 |
DisclosureSEC source: 0001599901-24-000152 · wk-form4_1726259097.xml · nonDerivative · entry 2 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,765 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.75 to $41.00. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:25 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 62,500 | $26.75 | $1,671,875.00 |
DisclosureSEC source: 0001599901-24-000152 · wk-form4_1726259097.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 22:47 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 10,106 | $39.13 | $395,444.75 |
DisclosureSEC source: 0001599901-24-000108 · wk-form4_1718923625.xml · nonDerivative · entry 2 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,765 F2 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of those PSUs that vested on June 17, 2024 as a result of achievement of the Performance Condition. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.09 to $39.13. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 22:47 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-24-000108 · wk-form4_1718923625.xml · nonDerivative · entry 3 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,765 F4 · shares: As a result of the achievement of the Performance Condition, on June 17, 2024, an additional 25,000 PSUs were earned by the Reporting Person on such date. On such date, such PSUs converted to time-based restricted stock units that will vest on December 17, 2024 subject to the Reporting Person's continued employment or service through such date. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 22:47 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-24-000108 · wk-form4_1718923625.xml · nonDerivative · entry 1 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,871 F1 · shares: Represents performance-based restricted stock units (PSUs). Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on September 11, 2023 and are eligible to vest upon the achievement of two company performance objectives. The PSUs reflected in this row represent the portion of the award that vested as a result of the achievement of the first performance objective (the Issuer's initiation of the Phase 3 HARBOR trial for del-desiran) (the Performance Condition). Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 20:12 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 4,129 | $10.13 | $41,826.77 |
DisclosureSEC source: 0001599901-24-000010 · wk-form4_1706040750.xml · nonDerivative · entry 2 Flanagan W. Michael · CIK 0001841990 · CSTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,871 F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs on January 20, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.